Anti-CX3CR1 Nanobody: Phase I started

Boehringer began a Phase I trial to evaluate single ascending doses of IV anti-CX3CR1 Nanobody. The start triggered a EUR8 million ($9 million) milestone payment to Ablynx from Boehringer under a 2007...